Abstract
Diabetes mellitus refers to a group of metabolic disorders which affect how the body uses glucose impacting approximately 9% of the population worldwide. This review covers the most recent technological advances envisioned to control and or reverse Type 1 diabetes mellitus (T1DM), many of which will also prove effective in treating the other forms of diabetes mellitus. Current standard therapy for T1DM involves multiple daily glucose measurements and insulin injections. Advances in glucose monitors, hormone delivery systems, and control algorithms generate more autonomous and personalised treatments through hybrid and fully automated closed-loop systems, which significantly reduce hypo-and hypergly-caemic episodes and their subsequent complications. Bi-hormonal systems that co-deliver glucagon or amylin with insulin aim to reduce hypoglycaemic events or increase time spent in target glycaemic range, respectively.
| Original language | English (Ireland) |
|---|---|
| Article number | 114280 |
| Journal | Advanced Drug Delivery Reviews |
| Volume | 185 |
| Issue number | 114280 |
| DOIs | |
| Publication status | Published - 1 Jun 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Algorithm
- Closed-loop
- Diabetes mellitus
- Glucagon
- Glucose responsive
- Hybrid
- Insulin
- Islet encapsulation
- Medical devices
Fingerprint
Dive into the research topics of 'Medical devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver